Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Applied Medical v. U.S. Surgical

This article was originally published in The Gray Sheet

Executive Summary

Tyco unit files motion to stay Oct. 15 central California federal district court order enjoining the sale of trocars using Applied Medical's '553 patent, including VersaStep, VersaPort, VisiPort, BluntPort and S.D. Port devices. Tyco also has appealed the enjoinment. The court determined in 2000 that Tyco infringed two other Applied Medical trocar patents (1"The Gray Sheet" July 24, 2000, In Brief). A trial is set for April 2003 to determine damages for past infringement of all three patents...

You may also be interested in...



Applied Medical v. U.S. Surgical

Tyco unit permanently enjoined from selling trocars using Applied Medical's '553 patent, including VersaStep, VersaPort, VisiPort, BluntPort and S.D. Port devices, effective Nov. 1, after central California federal appeals court denies Tyco's motion to stay injunction (1"The Gray Sheet" Oct. 28, 2002, In Brief). An April 2003 trial will determine damages...

Applied Medica

Tyco's U.S. Surgical division infringed two of Applied's patents covering the Universal Seal technology for minimally invasive surgery, the U.S. District Court for the Central District of California determines July 6 in granting an order for partial summary judgment. The trial is expected to take place in the first quarter of 2001. Applied Medica is seeking an injunction on the infringed products in addition to damages

Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa

The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT017349

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel